Phase4 Ventures spins out of Nomura

Phase4 Ventures spun out from Nomura after a buyout by its management team and a secondary investment in the existing portfolio by HarbourVest Partners. An undisclosed portion of Nomura Phase4's portfolio remains with Nomura. Phase4 Ventures will continue to manage existing investments for both HarbourVest and Nomura. Financial terms were not disclosed.

Among the Phase4 investments going to HarbourVest are gastrointestinal and autoimmune play Albireo (Gothenburg, Sweden), a spin-out from AstraZeneca plc (LSE:AZN; NYSE:AZN); infectious disease company Nabriva Therapeutics AG (Vienna, Austria), a spin-out from the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN); oncology and inflammation play Chroma Therapeutics Ltd. (Abingdon, U.K.); cancer company OncoMed Pharmaceuticals Inc. (Redwood City, Calif.); and infectious disease company Paratek Pharmaceuticals Inc. (Boston, Mass.). ...